Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Holly Reichard is active.

Publication


Featured researches published by Holly Reichard.


Schizophrenia Bulletin | 2018

S39. GPR139 AN OPHAN GPCR AFFECTING NEGATIVE DOMAINS OF SCHIZOPHRENIA

Joy Atienza; Holly Reichard; Victoria Mulligan; Jackie Cilia; Holger Monenschein; Deanna Collia; Jim Ray; Gavin Kilpatrick; Nicola Brice; Mark B. L. Carlton; Steve Hitchcock; Ged Corbett

Abstract Background Individuals with schizophrenia fail to appropriately use negative feedback to guide learning. These learning deficits are thought to arise from abnormalities in midbrain dopamine activity. The habenula is a well conserved paired structure that sits in the midline, adjacent to the third ventricle, and dorsal and posterior to the thalamus. Classic studies have shown that it is part of the reward pathway and functions with dopamine neurons in the ventral tegmental area (VTA) to mediate reward related signals, specifically aversive and negative stimulus (Hikosaka, 2010). Several studies point to pathology in the habenula as contributing to schizophrenia (Sandyk, 1992; Caputo et al., 1998; Shepard et al., 2006). Despite the many studies on the habenula, the precise function of the habenula remains unclear. Here we describe functional consequences of regulation of GPR139 an orphan GPCR that is specifically expressed in the CNS and enriched in the habenula (Matsuo et al., 2005) in mouse models of domain of schizophrenia. Methods Specific expression of mouse GPR139 in the habenula was evaluated using bacterial artificial chromosome translating ribosome affinity purification (bacTRAP) and confirmed by immunohistochemistry. GPR139-/- mice were generated by removal of a 736bp region encoding the seven transmembrane domain (7TM) domain. Knockout animals were maintained inbred on a 129/SvEv background and evaluated in behavioral models that reflect aspects of negative symptoms. High throughput screen (HTS) for small molecules was performed. We expressed full length GPR139 into CHO cells and screened a 600K library using a calcium assay to identify small molecule agonist. Hits were identified and physical properties optimized to produce a molecule suitable for in vivo evaluation. GPR139 agonist was testedin vivo in social interaction in Poly(I:C) and cognitive test in subchronic PCP, models of schizophrenia. Results Using bacTRAP we observed enriched expression of GPR139 in substance P positive- cells of the medial habenula. This expression was confirmed with immunohistochemistry. To determine if GPR139 regulates the known role of the habenula in learning, motivation, and social behaviour, GPR139 -/- animals were generated and phenotyped. These animals appeared normal and performed comparably to wild-type animals in a range of standard tasks. However, they were significantly impaired in models that reflect aspects of negative symptoms such as progressive ratio (Killeen et al., 2009; Heath et al., 2016), a measure of motivation and nest-building (Pedersen et al., 2014; Nakajima et al., 2013), a model of self-neglect. Furthermore, these animals showed deficits in novel object recognition model of working memory (Antunes and Biala, 2012). The small molecule agonist was observed to reverse deficits in models of schizophrenia including cognition in a subchronic PCP induced attentional set-shifting paradigm (Birrell and Brown, 2000) and social interaction in the Poly(I:C) maternal model (Meyer et al., 2008; Bitanihirwe et al., 2010). Discussion These findings identify an orphan receptor that plays an important role in habenular function. Modulation of this receptor may provide an opportunity to address an important unmet need in schizophrenia.


Archive | 2016

Tetrahydropyridopyrazines modulators of gpr6

Jason W. Brown; Stephen Hitchcock; Maria Hopkins; Shota Kikuchi; Holger Monenschein; Holly Reichard; Kristin Schleicher; Huikai Sun; Todd Macklin


Archive | 2013

QUINOXALINE DERIVATIVES AS GPR6 MODULATORS

Stephen Hitchcock; Holger Monenschein; Holly Reichard; Huikai Sun; Shota Kikuchi; Todd Macklin; Maria Hopkins


Archive | 2015

4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

Stephen Hitchcock; Betty Lam; Holger Monenschein; Holly Reichard


Archive | 2013

5-ht3 receptor antagonists

Stephen Hitchcock; Holdger Monenschein; Holly Reichard; Hulkai Sun; Shota Kikuchi; Todd Macklin; Maria Hopkins


Archive | 2017

4-OXO-3,4-DIHIDRO-1,2,3-BENZOTRIAZINAS COMO MODULADORES DE GPR139

Stephen A. Hitchcock; Holger Monenschein; Holly Reichard; Betty Lam


Archive | 2017

antagonistas de receptor 5-ht3

Holger Monenschein; Holly Reichard; Huikai Sun; Maria Hopkins; Shota Kikuchi; Stephen A. Hitchcock; Todd Macklin


Archive | 2017

4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139

Stephen A. Hitchcock; Betty Lam; Holger Monenschein; Holly Reichard


Archive | 2017

4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139

Stephen Hitchcock; Betty Lam; Holger Monenschein; Holly Reichard


Archive | 2016

Moduladores de tetrahidropiridopirazinas de gpr6.

Jason W. Brown; Stephen A. Hitchcock; Maria Hopkins; Holger Monenschein; Holly Reichard; Huikai Sun; Todd Macklin; Shota Kikuchi; Kristein Schleicher

Collaboration


Dive into the Holly Reichard's collaboration.

Top Co-Authors

Avatar

Shota Kikuchi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Huikai Sun

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Maria Hopkins

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Stephen Hitchcock

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Todd Macklin

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Betty Lam

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Holger Monenschein

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Holger Monenschein

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Jason W. Brown

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge